+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Oncology Companion Diagnostic Market Size, Share & Trends Analysis Report By Product & Service, By Technology (IHC, NGS), By Disease Type (Breast Cancer, Leukemia), By End Use, By Region, And Segment Forecasts, 2024 - 2030

  • PDF Icon

    Report

  • 150 Pages
  • August 2024
  • Region: Global
  • Grand View Research
  • ID: 5165399
Description Jump to:

Oncology Companion Diagnostic Market Growth & Trends

The global oncology companion diagnostic market size is expected to reach USD 8.38 billion by 2030, expanding at a CAGR of 8.7% from 2024 to 2030. Expanding access to important genomic information with the aid of companion diagnostics enables informed decision making for designing the targeted treatment approaches for their patients, thereby increasing demand for comprehensive genomic testing and oncology companion diagnostics.

The commercial launch of drugs including Gleevec (imatinib) and Herceptin (trastuzumab) that require Companion Diagnostics (CDx) testing before prescription has increased revenue generation in the oncology companion diagnostics field. This growth is expected to continue in the future owing to a substantial number of CDx associated oncology drugs in clinical trials. Apart from functioning as exclusive or inclusive tests for therapies, CDx also plays a crucial role during participant selection in clinical trials. This is because there is an increased potential for a novel drug candidate to show a better response rate if the patient has its biomarker target.

The economic incentives associated with the use of CDx have encouraged drug developers to combine their drugs with diagnostic tests. However, the diagnostic manufacturers face conflicting demands from payers/providers on one hand and drug manufacturers on the other hand. The regulatory bodies also have stringent policies to align the development timelines of diagnostics and drugs. Therefore, the diagnostic companies are expected to broaden their scope of CDx development instead of focusing on the attainment of a match between a single diagnostic with a specific drug.

Oncology Companion Diagnostic Market Report Highlights

  • The motor prosthetic devices segment dominated in terms of revenue share and accounted for over 42.8.0% of the market in 2023, followed by visual cochlear implants. Whereas, retinal neuroprosthetics were identified as one of the fastest growing market segment owing to the rising penetration and the increasing R&D efforts pertaining to product innovation.
  • The Spinal Cord Stimulation (SCS) segment held the largest share at over 49.2% owing to the analgesic property of the SCS therapy used in the treatment of ischemic pain, failed back surgery syndrome, and complex refractory pain syndrome. Furthermore, it finds applications in intraspinal and epidural microstimulation for inducing leg movements. In addition, technological advancements in this segment is expected to further boost market growth in the near future. The sacral Nerve Stimulation (SNS) is expected to be the fastest growing segment over the forecast period due to its applications in chronic intractable pelvic ache and neurogenic bladder.
  • In the applications segment, motor neuron disorders held the largest segment due to the rising incidences of Parkinson’s disease and epilepsy. For instance, as per the report published by Parkinson’s disease Foundation in 2012, approximately 60,000 Americans were diagnosed with Parkinson’s disease each year and the number is expected to grow further over the forecast period thereby fueling this segment’s growth.
  • In 2023, North America dominated the overall neuroprosthetics market at over 42.5% owing to the large presence of neural implants manufacturers, higher R&D investments, and the availability of funds from both government and private institutes. For instance, the Defense Advanced Research Project Agency (DARPA) and National Institute of Neurological Disorders and Stroke (NIH)in collaboration with the federal agencies are instrumental in providing funds to support R&D initiatives for the further development of neural implants.
  • Asia Pacific is anticipated to be the fastest growing segment due to the introduction of multinational healthcare establishments promoting safe and effective medical procedures along with the rising awareness levels amongst consumers.
  • Strategic collaborations and mergers & acquisitions are expected to keep the industry rivalry level high over the forecast period.

Why should you buy this report?

  • Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players worldwide.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listing for you to stay ahead of the curve
  • COVID-19's impact and how to sustain in these fast-evolving markets

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product & Services
1.2.2. Technology
1.2.3. Disease Type
1.2.4. End-use
1.2.5. Regional scope
1.2.6. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product & services and technology outlook
2.2.2. Disease type and end-use outlook
2.2.3. Regional outlook
2.3. Competitive Insights
Chapter 3. Oncology Companion Diagnostic Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increasing prevalence of cancer
3.2.1.2. Growing adoption of companion diagnostics
3.2.1.3. Rising emphasis on personalized medicine
3.2.2. Market restraint analysis
3.2.2.1. Complex regulatory landscape
3.2.2.2. Limited awareness and adoption in developing countries
3.3. Oncology Companion Diagnostic Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
Chapter 4. Oncology Companion Diagnostic Market: Product & Services Estimates & Trend Analysis
4.1. Global Oncology Companion Diagnostic Market: Product & Services Dashboard
4.2. Global Oncology Companion Diagnostic Market: Product& Services Movement Analysis
4.3. Global Oncology Companion Diagnostic Market by Product& Services, Revenue
4.4. Product
4.4.1. Product market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2. Instruments
4.4.2.1. Product market estimates and forecasts 2018 to 2030 (USD Million)
4.4.3. Consumables
4.4.3.1. Consumables market estimates and forecasts 2018 to 2030 (USD Million)
4.4.4. Software
4.4.4.1. Software market estimates and forecasts 2018 to 2030 (USD Million)
4.5. Services
4.5.1. Services market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. Oncology Companion Diagnostic Market: Technology Estimates & Trend Analysis
5.1. Global Oncology Companion Diagnostic Market: Technology Dashboard
5.2. Global Oncology Companion Diagnostic Market: Technology Movement Analysis
5.3. Global Oncology Companion Diagnostic Market by Technology, Revenue
5.4. Polymerase Chain Reaction (PCR)
5.4.1. Polymerase Chain Reaction (PCR) market estimates and forecasts 2018 to 2030 (USD Million)
5.5. Next-generation Sequencing (NGS)
5.5.1. Next-generation Sequencing (NGS) market estimates and forecasts 2018 to 2030 (USD Million)
5.6. Immunohistochemistry (IHC)
5.6.1. Immunohistochemistry (IHC) market estimates and forecasts 2018 to 2030 (USD Million)
5.7. In Situ Hybridization (ISH)/Fluorescence In Situ Hybridization (FISH)
5.7.1. In Situ Hybridization (ISH)/Fluorescence In Situ Hybridization (FISH) market estimates and forecasts 2018 to 2030 (USD Million)
5.8. Other Technologies
5.8.1. Other technologies market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. Oncology Companion Diagnostic Market: Disease Type Estimates & Trend Analysis
6.1. Global Oncology Companion Diagnostic Market: Disease Type Dashboard
6.2. Global Oncology Companion Diagnostic Market: Disease Type Movement Analysis
6.3. Global Oncology Companion Diagnostic Market by Disease Type, Revenue
6.4. Breast Cancer
6.4.1. Breast cancer market estimates and forecasts 2018 to 2030 (USD Million)
6.5. Non-small Cell Lung Cancer
6.5.1. Non-small cell lung cancer market estimates and forecasts 2018 to 2030 (USD Million)
6.6. Colorectal Cancer
6.6.1. Colorectal cancer market estimates and forecasts 2018 to 2030 (USD Million)
6.7. Leukemia
6.7.1. Leukemia market estimates and forecasts 2018 to 2030 (USD Million)
6.8. Melanoma
6.8.1. Melanoma market estimates and forecasts 2018 to 2030 (USD Million)
6.9. Prostate Cancer
6.9.1. Prostate cancer market estimates and forecasts 2018 to 2030 (USD Million)
6.10. Others
6.10.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. Oncology Companion Diagnostic Market: End-use Estimates & Trend Analysis
7.1. Global Oncology Companion Diagnostic Market: End-use Dashboard
7.2. Global Oncology Companion Diagnostic Market: End-use Movement Analysis
7.3. Global Oncology Companion Diagnostic Market by End-use, Revenue
7.4. Hospitals
7.4.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Million)
7.5. Pathology/Diagnostic Laboratory
7.5.1. Pathology/Diagnostic laboratory market estimates and forecasts 2018 to 2030 (USD Million)
7.6. Academic Medical Center
7.6.1. Academic medical center market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 8. Oncology Companion Diagnostic Market: Regional Estimates & Trend Analysis by Type, Tube Material, Application, and End Use
8.1. Regional Dashboard
8.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030
8.3. North America
8.3.1. U.S.
8.3.1.1. Key country dynamics
8.3.1.2. Regulatory framework/ reimbursement structure
8.3.1.3. Competitive scenario
8.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
8.3.2. Canada
8.3.2.1. Key country dynamics
8.3.2.2. Regulatory framework/ reimbursement structure
8.3.2.3. Competitive scenario
8.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
8.3.3. Mexico
8.3.3.1. Key country dynamics
8.3.3.2. Regulatory framework/ reimbursement structure
8.3.3.3. Competitive scenario
8.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
8.4. Europe
8.4.1. UK
8.4.1.1. Key country dynamics
8.4.1.2. Regulatory framework/ reimbursement structure
8.4.1.3. Competitive scenario
8.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
8.4.2. Germany
8.4.2.1. Key country dynamics
8.4.2.2. Regulatory framework/ reimbursement structure
8.4.2.3. Competitive scenario
8.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
8.4.3. France
8.4.3.1. Key country dynamics
8.4.3.2. Regulatory framework/ reimbursement structure
8.4.3.3. Competitive scenario
8.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
8.4.4. Italy
8.4.4.1. Key country dynamics
8.4.4.2. Regulatory framework/ reimbursement structure
8.4.4.3. Competitive scenario
8.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
8.4.5. Spain
8.4.5.1. Key country dynamics
8.4.5.2. Regulatory framework/ reimbursement structure
8.4.5.3. Competitive scenario
8.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
8.4.6. Norway
8.4.6.1. Key country dynamics
8.4.6.2. Regulatory framework/ reimbursement structure
8.4.6.3. Competitive scenario
8.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
8.4.7. Sweden
8.4.7.1. Key country dynamics
8.4.7.2. Regulatory framework/ reimbursement structure
8.4.7.3. Competitive scenario
8.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
8.4.8. Denmark
8.4.8.1. Key country dynamics
8.4.8.2. Regulatory framework/ reimbursement structure
8.4.8.3. Competitive scenario
8.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
8.5. Asia Pacific
8.5.1. Japan
8.5.1.1. Key country dynamics
8.5.1.2. Regulatory framework/ reimbursement structure
8.5.1.3. Competitive scenario
8.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
8.5.2. China
8.5.2.1. Key country dynamics
8.5.2.2. Regulatory framework/ reimbursement structure
8.5.2.3. Competitive scenario
8.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
8.5.3. India
8.5.3.1. Key country dynamics
8.5.3.2. Regulatory framework/ reimbursement structure
8.5.3.3. Competitive scenario
8.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
8.5.4. Australia
8.5.4.1. Key country dynamics
8.5.4.2. Regulatory framework/ reimbursement structure
8.5.4.3. Competitive scenario
8.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
8.5.5. South Korea
8.5.5.1. Key country dynamics
8.5.5.2. Regulatory framework/ reimbursement structure
8.5.5.3. Competitive scenario
8.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
8.5.6. Thailand
8.5.6.1. Key country dynamics
8.5.6.2. Regulatory framework/ reimbursement structure
8.5.6.3. Competitive scenario
8.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
8.6. Latin America
8.6.1. Brazil
8.6.1.1. Key country dynamics
8.6.1.2. Regulatory framework/ reimbursement structure
8.6.1.3. Competitive scenario
8.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
8.6.2. Argentina
8.6.2.1. Key country dynamics
8.6.2.2. Regulatory framework/ reimbursement structure
8.6.2.3. Competitive scenario
8.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
8.7. MEA
8.7.1. South Africa
8.7.1.1. Key country dynamics
8.7.1.2. Regulatory framework/ reimbursement structure
8.7.1.3. Competitive scenario
8.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
8.7.2. Saudi Arabia
8.7.2.1. Key country dynamics
8.7.2.2. Regulatory framework/ reimbursement structure
8.7.2.3. Competitive scenario
8.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
8.7.3. UAE
8.7.3.1. Key country dynamics
8.7.3.2. Regulatory framework/ reimbursement structure
8.7.3.3. Competitive scenario
8.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
8.7.4. Kuwait
8.7.4.1. Key country dynamics
8.7.4.2. Regulatory framework/ reimbursement structure
8.7.4.3. Competitive scenario
8.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 9. Competitive Landscape
9.1. Recent Developments & Impact Analysis, By Key Market Participants
9.2. Company/Competition Categorization
9.3. Vendor Landscape
9.3.1. List of key distributors and channel partners
9.3.2. Key customers
9.3.3. Key company market share analysis, 2023
9.3.4. Agilent Technologies, Inc.
9.3.4.1. Company overview
9.3.4.2. Financial performance
9.3.4.3. Product benchmarking
9.3.4.4. Strategic initiatives
9.3.5. Illumina, Inc.
9.3.5.1. Company overview
9.3.5.2. Financial performance
9.3.5.3. Product benchmarking
9.3.5.4. Strategic initiatives
9.3.6. QIAGEN
9.3.6.1. Company overview
9.3.6.2. Financial performance
9.3.6.3. Product benchmarking
9.3.6.4. Strategic initiatives
9.3.7. Thermo Fisher Scientific Inc.
9.3.7.1. Company overview
9.3.7.2. Financial performance
9.3.7.3. Product benchmarking
9.3.7.4. Strategic initiatives
9.3.8. Foundation Medicine, Inc.
9.3.8.1. Company overview
9.3.8.2. Financial performance
9.3.8.3. Product benchmarking
9.3.8.4. Strategic initiatives
9.3.9. Myriad Genetics, Inc.
9.3.9.1. Company overview
9.3.9.2. Financial performance
9.3.9.3. Product benchmarking
9.3.9.4. Strategic initiatives
9.3.10. F. Hoffmann-La Roche Ltd.
9.3.10.1. Company overview
9.3.10.2. Financial performance
9.3.10.3. Product benchmarking
9.3.10.4. Strategic initiatives
9.3.11. BioMérieux
9.3.11.1. Company overview
9.3.11.2. Financial performance
9.3.11.3. Product benchmarking
9.3.11.4. Strategic initiatives
9.3.12. Abbott
9.3.12.1. Company overview
9.3.12.2. Financial performance
9.3.12.3. Product benchmarking
9.3.12.4. Strategic initiatives
9.3.13. Leica Biosystems
9.3.13.1. Company overview
9.3.13.2. Financial performance
9.3.13.3. Product benchmarking
9.3.13.4. Strategic initiatives
9.3.14. Guardant Health, Inc.
9.3.14.1. Company overview
9.3.14.2. Financial performance
9.3.14.3. Product benchmarking
9.3.14.4. Strategic initiatives
9.3.15. EntroGen, Inc.
9.3.15.1. Company overview
9.3.15.2. Financial performance
9.3.15.3. Product benchmarking
9.3.15.4. Strategic initiatives
List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Global Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
Table 4 Global Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
Table 5 Global Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
Table 6 Global Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
Table 7 Global Oncology Companion Diagnostic, by Region, 2018 - 2030 (USD Million)
Table 8 North America Oncology Companion Diagnostic, by Country, 2018 - 2030 (USD Million)
Table 9 North America Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
Table 10 North America Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
Table 11 North America Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
Table 12 North America Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
Table 13 U.S. Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
Table 14 U.S. Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
Table 15 U.S. Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
Table 16 U.S. Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
Table 17 Canada Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
Table 18 Canada Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
Table 19 Canada Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
Table 20 Canada Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
Table 21 Mexico Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
Table 22 Mexico Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
Table 23 Mexico Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
Table 24 Mexico Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
Table 25 Europe Oncology Companion Diagnostic, by Country, 2018 - 2030 (USD Million)
Table 26 Europe Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
Table 27 Europe Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
Table 28 Europe Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
Table 29 Europe Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
Table 30 Germany Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
Table 31 Germany Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
Table 32 Germany Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
Table 33 Germany Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
Table 34 UK Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
Table 35 UK Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
Table 36 UK Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
Table 37 UK Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
Table 38 France Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
Table 39 France Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
Table 40 France Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
Table 41 France Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
Table 42 Italy Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
Table 43 Italy Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
Table 44 Italy Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
Table 45 Italy Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
Table 46 Spain Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
Table 47 Spain Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
Table 48 Spain Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
Table 49 Spain Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
Table 50 Denmark Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
Table 51 Denmark Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
Table 52 Denmark Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
Table 53 Denmark Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
Table 54 Sweden Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
Table 55 Sweden Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
Table 56 Sweden Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
Table 57 Sweden Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
Table 58 Norway Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
Table 59 Norway Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
Table 60 Norway Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
Table 61 Norway Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
Table 62 Asia Pacific Oncology Companion Diagnostic, by Country, 2018 - 2030 (USD Million)
Table 63 Asia Pacific Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
Table 64 Asia Pacific Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
Table 65 Asia Pacific Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
Table 66 Asia Pacific Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
Table 67 China Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
Table 68 China Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
Table 69 China Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
Table 70 China Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
Table 71 Japan Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
Table 72 Japan Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
Table 73 Japan Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
Table 74 Japan Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
Table 75 India Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
Table 76 India Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
Table 77 India Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
Table 78 India Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
Table 79 South Korea Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
Table 80 South Korea Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
Table 81 South Korea Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
Table 82 South Korea Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
Table 83 Australia Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
Table 84 Australia Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
Table 85 Australia Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
Table 86 Australia Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
Table 87 Thailand Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
Table 88 Thailand Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
Table 89 Thailand Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
Table 90 Thailand Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
Table 91 Latin America Oncology Companion Diagnostic, by Country, 2018 - 2030 (USD Million)
Table 92 Latin America Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
Table 93 Latin America Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
Table 94 Latin America Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
Table 95 Latin America Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
Table 96 Brazil Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
Table 97 Brazil Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
Table 98 Brazil Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
Table 99 Brazil Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
Table 100 Argentina Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
Table 101 Argentina Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
Table 102 Argentina Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
Table 103 Argentina Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
Table 104 Middle East & Africa Oncology Companion Diagnostic, by Country, 2018 - 2030 (USD Million)
Table 105 Middle East & Africa Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
Table 106 Middle East & Africa Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
Table 107 Middle East & Africa Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
Table 108 Middle East & Africa Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
Table 109 South Africa Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
Table 110 South Africa Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
Table 111 South Africa Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
Table 112 South Africa Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
Table 113 Saudi Arabia Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
Table 114 Saudi Arabia Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
Table 115 Saudi Arabia Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
Table 116 Saudi Arabia Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
Table 117 UAE Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
Table 118 UAE Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
Table 119 UAE Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
Table 120 UAE Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
Table 121 Kuwait Oncology Companion Diagnostic, by Product & Services, 2018 - 2030 (USD Million)
Table 122 Kuwait Oncology Companion Diagnostic, by Technology, 2018 - 2030 (USD Million)
Table 123 Kuwait Oncology Companion Diagnostic, by Disease Type, 2018 - 2030 (USD Million)
Table 124 Kuwait Oncology Companion Diagnostic, by End Use, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Market research process
Fig. 2 Information Procurement
Fig. 3 Primary Research Pattern
Fig. 4 Market Research Approaches
Fig. 5 Value Chain-Based Sizing & Forecasting
Fig. 6 Market Formulation & Validation
Fig. 7 Oncology Companion Diagnostic Market Segmentation
Fig. 8 Market Snapshot, 2023
Fig. 9 Market Trends & Outlook
Fig. 10 Market Driver Relevance Analysis (Current & Future Impact)
Fig. 11 Market Restraint Relevance Analysis (Current & Future Impact)
Fig. 12 Market Challenge Relevance Analysis (Current & Future Impact)
Fig. 13 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
Fig. 14 Porter’s Five Forces Analysis
Fig. 15 Global Oncology Companion Diagnostic Market: Product & Services Movement Analysis
Fig. 16 Global Oncology Companion Diagnostic Market, for Product, 2018 - 2030 (USD Million)
Fig. 17 Global Oncology Companion Diagnostic Market, for Services, 2018 - 2030 (USD Million)
Fig. 18 Global Oncology Companion Diagnostic Market: Technology Movement Analysis
Fig. 19 Global Oncology Companion Diagnostic Market, for Polymerase Chain Reaction (PCR), 2018 - 2030 (USD Million)
Fig. 20 Global Oncology Companion Diagnostic Market, for Next-generation Sequencing (NGS), 2018 - 2030 (USD Million)
Fig. 21 Global Oncology Companion Diagnostic Market, for Immunohistochemistry (IHC), 2018 - 2030 (USD Million)
Fig. 22 Global Oncology Companion Diagnostic Market, for In situ hybridization (ISH)/Fluorescence in situ hybridization (FISH), 2018 - 2030 (USD Million)
Fig. 23 Global Oncology Companion Diagnostic Market, for Other Technologies, 2018 - 2030 (USD Million)
Fig. 24 Global Oncology Companion Diagnostic Market: Disease Type Movement Analysis
Fig. 25 Global Oncology Companion Diagnostic Market, for Breast Cancer, 2018 - 2030 (USD Million)
Fig. 26 Global Oncology Companion Diagnostic Market, for Non-small Cell Lung Cancer, 2018 - 2030 (USD Million)
Fig. 27 Global Oncology Companion Diagnostic Market, for Colorectal Cancer, 2018 - 2030 (USD Million)
Fig. 28 Global Oncology Companion Diagnostic Market, for Leukemia, 2018 - 2030 (USD Million)
Fig. 29 Global Oncology Companion Diagnostic Market, for Melanoma, 2018 - 2030 (USD Million)
Fig. 30 Global Oncology Companion Diagnostic Market, for Prostate Cancer, 2018 - 2030 (USD Million)
Fig. 31 Global Oncology Companion Diagnostic Market, for Others, 2018 - 2030 (USD Million)
Fig. 32 Global Oncology Companion Diagnostic Market: End-use Movement Analysis
Fig. 33 Global Oncology Companion Diagnostic Market, for Hospitals, 2018 - 2030 (USD Million)
Fig. 34 Global Oncology Companion Diagnostic Market, for Pathology/Diagnostic Laboratory, 2018 - 2030 (USD Million)
Fig. 35 Global Oncology Companion Diagnostic Market, for Academic Medical Center, 2018 - 2030 (USD Million)
Fig. 36 Regional Marketplace: Key Takeaways
Fig. 37 Regional Outlook, 2023 & 2030
Fig. 38 Global Oncology Companion Diagnostic Market: Region Movement Analysis
Fig. 39 North America Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
Fig. 40 U.S. Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
Fig. 41 Canada Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
Fig. 42 Mexico Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
Fig. 43 Europe Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
Fig. 44 Germany Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
Fig. 45 UK Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
Fig. 46 France Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
Fig. 47 Italy Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
Fig. 48 Spain Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
Fig. 49 Denmark Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
Fig. 50 Sweden Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
Fig. 51 Norway Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
Fig. 52 Asia Pacific Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
Fig. 53 Japan Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
Fig. 54 China Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
Fig. 55 India Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
Fig. 56 Australia Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
Fig. 57 South Korea Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
Fig. 58 Thailand Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
Fig. 59 Latin America Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
Fig. 60 Brazil Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
Fig. 61 Argentina Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
Fig. 62 Middle East and Africa Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
Fig. 63 South Africa Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
Fig. 64 Saudi Arabia Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
Fig. 65 UAE Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)
Fig. 66 Kuwait Oncology Companion Diagnostic Market, 2018 - 2030 (USD Million)

Companies Mentioned

  • Agilent Technologies, Inc.
  • Illumina, Inc.
  • QIAGEN
  • Thermo Fisher Scientific Inc.
  • Foundation Medicine, Inc.
  • Myriad Genetics, Inc.
  • F. Hoffmann-La Roche Ltd.
  • BioMérieux
  • Abbott
  • Leica Biosystems
  • Guardant Health, Inc.
  • EntroGen, Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages150
PublishedAugust 2024
Forecast Period2023 - 2030
Estimated Market Value ( USD ) in 2023 $ 4.78 Billion
Forecasted Market Value ( USD ) by 2030 $ 8.38 Billion
Compound Annual Growth Rate8.7%
Regions CoveredGlobal
No. of Companies Mentioned12

Related Topics

Related Reports

Global Companion Diagnostics Market by Technology (Immunohistochemistry, In Situ Hybridization, Next-Generation Sequencing), Indication (Cancer, Cardiovascular Diseases, Infectious Diseases), End-user - Forecast 2024-2030 - Product Image

Global Companion Diagnostics Market by Technology (Immunohistochemistry, In Situ Hybridization, Next-Generation Sequencing), Indication (Cancer, Cardiovascular Diseases, Infectious Diseases), End-user - Forecast 2024-2030

  • Report
  • 195 Pages
  • Global
From
Global Oncology Companion Diagnostics Market Report 2024 - Product Image

Global Oncology Companion Diagnostics Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Oncology Companion Diagnostic Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F - Product Image

Oncology Companion Diagnostic Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F

  • Report
  • 179 Pages
  • Global
From
Companion Diagnostics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029) - Product Image

Companion Diagnostics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029)

  • Report
  • 120 Pages
  • Global
From
Companion Diagnostics - Global Strategic Business Report - Product Image

Companion Diagnostics - Global Strategic Business Report

  • Report
  • 196 Pages
  • Global
From

About the Market

Oncology Companion Diagnostics (OCD) are a type of diagnostic test used to identify and monitor cancer patients. These tests are used to detect the presence of cancer, determine the type of cancer, and assess the patient's response to treatment. OCDs are used to identify genetic mutations that may be associated with the development of cancer, as well as to identify biomarkers that can be used to predict the risk of cancer recurrence. OCDs are also used to monitor the progression of cancer and to determine the effectiveness of treatment. OCD tests are typically performed in conjunction with other diagnostic tests, such as imaging and biopsy. They are used to provide a more comprehensive picture of the patient's cancer and to guide treatment decisions. Companies in the Oncology Companion Diagnostics market include Roche, Illumina, Thermo Fisher Scientific, Agilent Technologies, and Qiagen. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.